Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
pgsd, could you link the source from where you got those comments by LL? Thanks. :) Sentiment
pgsd
Saturday, 04/25/20 12:09:18 PM
Re: sentiment_stocks post# 280006
Post # of 280094
https://www.regulations.gov/document?D=FDA-2019-D-4964-0071
RuleofK
Saturday, 04/25/20 01:17:59 PM
Re: sentiment_stocks post# 280006
Post # of 280094
See ATLnsider post number 272905. These statements seem almost to have been taken from this interview. Not sure if she posted them on FDA site or someone else did???
https://billmalloy.info/qa-with-linda-liau/
Brain Tumor Center Talk
March 23
Bill Malloy
@bmalloyIII
My very personal interview with Linda Liau at #UCLA who saved my #wife's life in our battle with #cancer and #glioblastoma
Q&A with Linda Liau | Bill Malloy
Dr. Linda Liau is widely recognized as one of the world’s most forward-thinking brain surgeons.
https://billmalloy.info/qa-with-linda-liau/
My very personal interview with Linda Liau at #UCLA who saved my #wife's life in our battle with #cancer and #glioblastoma
— Bill Malloy (@bmalloyIII) March 23, 2020
@sloan_kettering @UCLA @theNCI @parkerici @StanfordMed @cityofhope @briansin @JoeBiden https://t.co/8VOIz9gGdz
I must admit I don’t trust Elsa, the Siberian Sealpoint.
Elsa the Siberian Sealpoint is relaxed and cool as JimmyChill @jimcramer #CNBC she knows what she owns in this market and is adding on any dips #stockstowatch #biotech #ecommerce two #microcaps trading at a 90% discount to fair valuation $BLCM $WEYL @IAmBiotech @iancassel pic.twitter.com/fjBihNESFG
— Chris LaCoursiere (@ChrisLaCoursie1) April 8, 2020
7/9/2020 (related to Sawston)
hankmanhub,
Ike’s transcript is a word-by-word transcript.(I have the audio) He did a great job! Thank you Ike!
In Europe, more preparations were made than many people realize, imho, and more money was recently injected.
17:10 Session 1: The ATMP manufacturing landscape in the UK and the current challenges
17:10 – Keynote – Ian McCubbin, OBE, Chair RoslinCT and Manufacturing advisory group Innovate
17:25 – Panel Discussion
Prof Uta Griesenbach, Imperial College London
Matthew Durdy, CBO, Cell and Gene Therapy Catapult
Dr James Miskin, CTO, Oxford Biomedica
Prof Farzin Farzaneh, King’s College London
Peter Coleman, CEO, Cobra Biologics
Dr Mike Scott, COO, Advent Bioservices
Great session with interesting takes on #ATMP manufacture.
Great session with interesting takes on #ATMP manufacture https://t.co/6iMWm2ujTe
— Kamar Johnson (@johnson_kamar) March 12, 2020
I spoke with Dave and he mentioned that it was on the advice of the SAB and the steering committee that they'd received some time ago that they add obtaining this data to the process.
The mutation status of the IDH1 gene has not yet been investigated for this trial, as this factor was not included in trial designs a decade ago when this trial began. It will be collected and analyzed later, but is unlikely to explain the overall survival results, as the mutation associated with prolonged survival occurs in less than 10% of newly diagnosed glioblastoma patients [27].
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
IkeEsq,
Thank you for the transcription!
As I've previously mentioned, I believe Duffy left on Friday, 3/27.
Research Medical Science Director
Company Name
Merck Full-time
Dates Employed Mar 2020 – Present
Employment Duration 2 mos
Location Weston, Florida, United States
https://www.linkedin.com/in/kevin-duffy-9519831/
3 6 9 13 15
Sentiment,
Q1
Can Linda Powers confirm that the Autolomous employees (https://www.autolomous.com/) have been working with Northwest Biotherapeutics on developing & deploying their AutoloMATE eBMR solution (Phase 1) and that the Autolomous team are NOW busy working remotely, building Proof-of-concepts with Northwest Biotherapeutics and developing the next stages (Phase 2 and Phase 3) of their AutoloMATE platform?
Q2
At the beginning of the year, important information about the future of Northwest Biotherapeutics in the UK was available on the following website: https://www.mill-lane-sawston.co.uk/.
Was Northwest Biotherapeutics one of the initiators for the construction of this website and why is the information currently not available?
(Note: IMO only a minority of the NWBO ihub followers saved the information on their hard drive.)
Q3 (Less important)
On March 16 there is a new ‘Handelsregister–Bekanntmachung‘ ( Commercial Register Announcement ?) of Northwest Biotherapeutics GmbH.
Can Linda Powers give us an update of what is going on in Germany (the German subsidiary NW Bio GmbH)?
Is Fanny Schömann still the German representative and what is her relationship with Advent bioservices? (If any, but IMO there is evidence of that relationship)
Q4 (Less important, only question out of personal curiosity)
Late summer 2016 Linda Liau announced that 331 patients have been enrolled in the trial.
Why has Northwest Biotherapeutics waited three months to officially disclose this important information? (https://nwbio.com/nw-bio-provides-update-about-phase-3-trial-of-dcvax-l-for-newly-diagnosed-glioblastoma-multiforme-brain-cancer/)
ATLnsider,
Thank you for posting this:https://billmalloy.info/qa-with-linda-liau/
March 23
Bill Malloy
@bmalloyIII
My very personal interview with Linda Liau at #UCLA who saved my #wife's life in our battle with #cancer and #glioblastoma
Q&A with Linda Liau | Bill Malloy
Dr. Linda Liau is widely recognized as one of the world’s most forward-thinking brain surgeons.
https://billmalloy.info/qa-with-linda-liau/
My very personal interview with Linda Liau at #UCLA who saved my #wife's life in our battle with #cancer and #glioblastoma
— Bill Malloy (@bmalloyIII) March 23, 2020
@sloan_kettering @UCLA @theNCI @parkerici @StanfordMed @cityofhope @briansin @JoeBiden https://t.co/8VOIz9gGdz
Why don't we know how many patients enrolled in Germany? Hint; maybe to protect the blind and long term data. There are 17 unenrolled SOC patients left out of this trial with last report of improving long term survival benefit from later enrolled patients which is the part of the trial where lower absolute lymphocyte count patients came from. Fraunhofer claimed to have enrolled only to the point of statistical necessity and there is evidence that a German woman's husband would have been placed into the SOC/placebo arm but was kept out of the trial.
Dan88,
I wonder if Linda Liau was here:
Grand Rounds
Department of Neurological Surgery University of Miami School of Medicine
March 2020
Lois Pope LIFE Center, 7th floor, Apex Center
Mar. 5
7:30-8:30 Visiting Professor:
The role of immunotherapy in gliomas
Linda Liau, MD, PhD, MBA
Chair of Neurosurgery, UCLA
http://neurosurgery.med.miami.edu/documents/Grand_Rounds_March_2020.pdf
The only comment I found on twitter about this event is this:
Michael Ivan, MD, MBS
Great talk this morning by Dr. de la Fuente
@delaFuenteNOnc on IDH1 targeted drugs in gliomas! Excited for our phase 3 trial which just started for #lowgradegliomas here at UM (#firstinflorida). #braincancer #cureglioblastoma
@SylvesterCancer
@umneurosurgery
@UMiamiHealth
Great talk this morning by Dr. de la Fuente @delaFuenteNOnc on IDH1 targeted drugs in gliomas! Excited for our phase 3 trial which just started for #lowgradegliomas here at UM (#firstinflorida). #braincancer #cureglioblastoma @SylvesterCancer @umneurosurgery @UMiamiHealth pic.twitter.com/uzBLZ8xBCD
— Michael Ivan, MD, MBS, FAANS (@michaelivanmd) March 6, 2020
Longfellow95,
Thank you for the information (Huawei site plan, as proposed)
A year ago:
Huawei - An artist's impression of the planned R&D site on the old Spicers area (8830218)
https://www.cambridgeindependent.co.uk/news/chinese-ict-giant-huawei-has-bought-iconic-spicers-stationary-site-in-sawston-for-redevelopment-9067661/
Today:
Huawei site, Sawston (27749479)
https://www.cambridgeindependent.co.uk/news/huawei-submits-revised-plans-for-r-d-centre-in-sawston-that-would-create-350-jobs-9097984/
Symposium Agenda – Saturday, March 7, 2020 UTSW T. Boone Pickens Auditorium
10:15 – 11:00 am - Role of Immunotherapy in Glioma - Linda Liau, M.D.
https://cme.utsouthwestern.edu/sites/default/files/Agenda_Bass2020_02.10.20mv.pdf
Mark Goldberg
@MarkGoldbergMD
So sorry that Dr. Liau was unable to join us for this conference! Another time...
So sorry that Dr. Liau was unable to join us for this conference! Another time...
— Mark Goldberg (@MarkGoldbergMD) March 7, 2020
Is this current or old stuff?
Whois Record for Mill-Lane-SawsTon.co.uk
How does this work?
Domain Profile
Registrar Status
Dates 56 days old
Created on 2020-01-09
Expires on 2021-01-09
Updated on 2020-01-15
Tech Contact —
IP Address 46.30.213.199 - 2,450 other sites hosted on this server
IP Location Denmark - Hovedstaden - Copenhagen - One.com A/s
ASN Denmark AS51468 ONECOM, DK (registered Sep 01, 2010)
Hosting History 1 change on 2 unique name servers over 0 year
Website
Website Title Mill Lane Sawston – Northwest Biotherapeutics
Server Type Apache
Response Code 200
Whois Record ( last updated on 2020-03-05 )
Flipper,
That's page 1. See my post 268309. (https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154084831)
A glimpse inside the world of cell therapy with Simone. An interesting video tour from Novartis GMP cellular manufacturing.
The Brain Tumour Charity
@BrainTumourOrg
We're incredibly sad to learn of @Sclavicus passing today. He was a huge advocate for the brain tumour community and his writing inspired so many. He used his platform to raise awareness and call for more research into this devastating disease. He will be sorely missed.
We're incredibly sad to learn of @Sclavicus passing today. He was a huge advocate for the brain tumour community and his writing inspired so many. He used his platform to raise awareness and call for more research into this devastating disease. He will be sorely missed. pic.twitter.com/RgcCl1qaCH
— The Brain Tumour Charity (@BrainTumourOrg) March 5, 2020
Martino was an inspiration to everyone in our community
Today we have heard the incredibly sad news of Martino Sclavi’s passing. He has been a driving force in much of our work and a huge advocate for the entire brain tumour community.
Thursday 5 March 2020
https://www.thebraintumourcharity.org/media-centre/news/charity-news/martino-was-inspiration-everyone-our-community/
That is correct.
But in the" Who are we" section it had both logos with Advent actually on top.
Why do NorthWest Biotherapeutics want to operate in the UK specifically?
The UK has a growing biotech industry and provides us with exceptional opportunities for growth; Cambridge is filled with high-level professionals and already has some of the existing infrastructure that will help support the development and success of our innovative technology.
Our cancer technology has the potential to revolutionise cancer treatments and we are working alongside the National Institute for Health and Care Excellence to bring forward our vaccines as soon as possible. We believe that developing our advanced cell manufacturing vaccine in the UK will be the quickest and most effective way of introducing this vital technology.
6. Advent has announced plans for 450 employees in Sawston.
What other benefits will NorthWest Biotherapeutics bring to the local area?
NorthWest Biotherapeutics seeks to bring benefits directly to the local people. Alongside the introduction of effective cancer treatments nationally, we hope that our presence in Sawston and the wider Cambridge area can bring a wider positive community impact.
Our ambitious five-year growth programme will see us create up to 450 jobs across all levels, boosting the local economy and contributing to the growth of the regional biotech sector. We are also in the process of developing an outreach programme that will engage local schools, focusing on education and skills development alongside sparking youth interest in the biotech sector. We are seeking to engage with the wider local community not only to raise awareness of our work, but to involve the local community in our vision.
Our work is not profit based – we are committed to reinvesting any funds that are generated during the time of our expansion into further research and development for treatments. We hope to be a part of the next phase of growth in Sawston, and we hope that our expansion in the area will bring positive impacts on the local, national and international level.
Longfellow95,
Thank you for the information. I didn’t know that some of the 17 acres is designated Green Belt.
Re: post 268512
Advents plan is 450 employees, and to supply Europe for GBM, it would have to be bigger than Cognate to serve that purpose. (Flipper)
Where did you see that?
Why stop at 450?
Even if they brought into service a third suite that would be 6000 sq ft.
Cognate is 80,000 sq ft.
"Interesting", the link that I provided on Friday is no longer accessible.
https://www.mill-lane-sawston.co.uk/
Seems he has a perfect smile in this picture.
tryn2,
It is an older photo. Al Musella updated his profile picture one week after he met Dr. Marnix Bosch. (SNO 2019.)
SNO Update
11-25-2019, 03:30 PM
Hi. Just got back from SNO (Society of Neuro-oncology annual meeting). Excellent meeting - overwheling with the amount of information presented. I am going to mention a few of the highlights and welcome others who went to the meeting to post their thoughts.
11-25-2019, 03:51 PM
DCVAX: No updated data was presented but we had a nice meeting with all of the advocacy groups and Northwest bio. They went over the unblinded data that they presented last time and said they will present the final results "soon". I pressed them on that and they said they know but can't tell me. I get the feeling it is going to be pretty good. The longer they wait the better the data will look and it has been a long time.
https://forum.virtualtrials.org/forum/main-forum/174-sno-update
December 3, 2019
Al Musella changed his current profile picture on Facebook.
Look at the background!
https://www.facebook.com/photo.php?fbid=10157886702749485&set=a.428489109484&type=3&theater
Who's mouth did these pearls recently drop from?
“The patient is the client at the FDA.”
“The sciences is changing and should guide our decisions.”
“Are we acting in the best interests of the patient, or are we adhering to regulatory orthodoxy?”
“And when we act in the best interests of patients, we are always right.”
“There are circumstances when a randomized trial does not provide the relevant answers, or may not be the best approach.”
They are from Richard Pazdur, who heads the FDA Oncology Center of Excellence, when he spoke at the recent Cancer Drug Development Forum (CDDF) Spring Conference in the Netherlands, on February 12, 2020, was about “FDA Guidelines” as it pertains to “Regulatory Guidance on Oncology Drug Development”.
Sentiment,
The website came to my attention two weeks ago but I don't know how old it is.
If it's new, then they could be adding a third, as I'd understood there to be just two.
Phase 1 of Advent Bioservices’ own new facility in Cambridgeshire, is due to be licensed and operational from Q3 2019 and includes two completed suites (185m2 each), comprising B, C and PD/QC labs, offices and storage space. This facility is due to bring to market 199 m2 of cleanroom footprint (including MAL & PAL areas) in its first phase. However, the site has capacity for a further ~7,500 m2 of additional development.
Sentiment,
On that first link;
The Vision Centre in Sawston is fully operational and is currently being fitted out with three ‘cleanroom’ suites, to be used by NW Bio as well as by other organisations that work in advanced cell manufacturing.
I do not know if this information has been posted before and if so then it might be a good refreshment.(The Vision Centre - Northwest Biotherapeutics - Advent Bioservices)
Northwest Biotherapeutics (NW Bio) along with our partner, Advent Bioservices, is building one of the premier advanced manufacturing facilities in the world, in the Vision Centre on the former Spicers site. This facility will produce personalised immune cell therapies for cancer and other diseases, as well as regenerative medicine cell therapies. The development of the Vision Centre also includes large training facilities to provide specialised job training for this advanced manufacturing.
We hope that our presence in Cambridge will contribute to the local, regional and national economy and that our innovative technology can change the lives of cancer patients in the UK.
The Vision Centre
The Vision Centre in Sawston is fully operational and is currently being fitted out with three ‘cleanroom’ suites, to be used by NW Bio as well as by other organisations that work in advanced cell manufacturing. Once complete, the Vision Centre will play a crucial role in allowing life-saving treatments to reach patients across the rest of Europe.
Land North of Mill Lane
Northwest Biotherapeutics acquired a site to the east of our existing Vision Centre in Sawston, with one possibility being to develop this for housing, some of which could be utilised by staff at the Vision Centre. Due to the nature of advanced manufacturing, blood and biopsy samples can arrive at any time, meaning we must have staff in close proximity to ensure the safe delivery, storage and processing of sensitive materials.
We are promoting the site through the Greater Cambridge Local Plan process and will be consulting with the community. Our aspiration for the site is that it will enhance our offering at the Vision Centre and support the services and other commercial and public facilities already in Sawston.
Our vision for the site at Sawston is one of partnership and growth with the community in and around the village, with employment opportunities at the Vision Centre being an importantpart of the Sawston local economy going forward, just as Spicers was in the past.
Meirluc,
DCVax-L was made for Jim Power (second time) by Advent Bioservices.
Ryta Power
April 6, 2019 ·
What a whirl wind of a trip to Cambridge and London, UK. but the vaccine is now being made! We are all wiped out, especially Jim. London is very hard to travel in with someone in a wheelchair but we found the English to be extremely polite and very helpful. Nice to be in our own beds. A great big thanks to my amazing Kristyn for being my rock in UK and Kathryn for holding the fort back home in Edmonton. Thanks for the many prayers and positive vibes for a safe journey! They worked.
Today we celebrate my Dad passing the 5-year milestone with GBM. We are thankful for the ongoing support from the CCI Edmonton and Northwest Biotherapeutics, and especially for the hours of caregiving my Mom offers every single day! Go Dad!
#GBM #Glioblastoma $NWBO
Today we celebrate my Dad passing the 5-year milestone with GBM. We are thankful for the ongoing support from the CCI Edmonton and Northwest Biotherapeutics, and especially for the hours of caregiving my Mom offers every single day! Go Dad! #GBM #Glioblastoma $NWBO pic.twitter.com/PlypOApbpk
— Kristyn Power, CFA (@KristynPower) July 28, 2019
My Dad was dx with #GBM in 2014 and started #DCVax-L after his third surgery in 2015. It is now 2020 and he is stable. I just enjoyed another holiday season with my dad, thank you $NWBO.
My Dad was dx with #GBM in 2014 and started #DCVax-L after his third surgery in 2015. It is now 2020 and he is stable.
— Kristyn Power, CFA (@KristynPower) January 9, 2020
I just enjoyed another holiday season with my dad, thank you $NWBO. ♥️ pic.twitter.com/YrsxIwNWta
Two new career opportunities at Advent Bioservices since the launch of their new website last week.
JOB VACANCY: Clinical Co-ordinator
The Clinical Coordinator is responsible for facilitating the relationship between Advent BioServices manufacturing team, the client, blood collection centres and couriers.
You will work closely with GMP Production Scientists and Quality Assurance staff and facilitate the efficient delivery of cellular therapy products for clinical use. They will ensure that appropriate guidelines are available to third party sites and that appropriate documentation, such as virology screening and patient consent, is received to allow manufacture of products. The post holder will visit UK clinical sites if required and provide support and training to hospital clinical teams.
As Clinical Coordinator you will demonstrate a pro-active autonomous approach with strong communication skills.
Key responsibilities for this role:
• Scheduling and communication for patients and the manufacturing team
• Working with the Manufacturing Team and the Quality Team to ensure that the procurement, manufacture, transportation and storage of tissue and cells is compliant with HTA and MHRA regulations
• Ensuring that contracts with all relevant stakeholders required for the manufacture process are in place, such as SLAs and MTAs
• Provide training to Apheresis collection centres, administration centres and couriers to ensure that tissues and cells are handled and transported in the correct conditions and in a safe manner
https://www.adventbio.uk/job-clinical-coordinator
JOB VACANCY: Validation Lead Scientist.
We are looking for a GMP experienced validation/qualification professional to progress their careers with us in the exciting area of cell & gene therapies. As Validation Lead you will work across GMP manufacturing, Quality Control laboratory facilities and the Cryostorage facility to ensure that all aspects of validation comply with relevant regulations.
Key responsibilities for this role:
• To support validation activities including equipment, facilities, processes and cleaning. This will include cleanrooms, medical gas supply and computer systems including environmental monitoring systems
• To co-ordinate validation/qualification and change control activities. Work with external contractors and supplies to ensure that a schedule is maintained, reports written on time and related documents kept current
• To agree scope of validation activities in line with company and regulatory requirements
• Author/approver of validation lifecycle documentation and reviews
• To internally promote validation activities, prepare training material and carry out in-house training in validation
• To support audits and inspections including inspections from regulatory bodies
https://www.adventbio.uk/job-validation-lead-scientist
Pilar Velasco Sevillano.
GMP Production Scientist at Advent Bioservices
Cambridge, United Kingdom
Currently, I am involved in a fabulous project, setting up a new manufacturing facilities based in Cambridge, where in the nearly future we could offer an immunotherapy treatment for patients with GB (Glioblastoma Multiform)
I enjoy compounding and learning new skills that are different from my university experience. I also like the fact that my work is able to help people, as we manufacture a "Specials" dendritic cell vaccine for GBM patients.
Sentiment,
Thank you!
Julia Post Guenther
Honored to have hosted UCLA, Dr. Linda Liau and members of her staff who traveled down to talk to us about the advances in neurosurgery. So grateful
meirluc,
I'm more and more of the opinion that the last 31-32 patients were not all treatment patients. I believe that possibly about 2 Canadian placebo patients were included in the last 31-32 patients.
There were 170 patients with <800 and 161 with >800 ALC in the trial.
Patients must have adequate bone marrow function (e.g., hemoglobin >10 g/dl, white blood count 3600-11,000mm3, absolute granulocyte count ≥1,500/mm3, absolute lymphocyte count ≥1,000/mm3, and platelet count ≥100K/mm3. Eligibility level of hemoglobin can be reached by transfusion.
https://clinicaltrials.gov/ct2/show/NCT00045968?cond=DCVax-L&draw=2&rank=3
Determined at pre-leukapheresis visit
• Patients must have adequate bone marrow function prior to each leukapheresis procedure (hemoglobin >10 g/dl or >100g/L, white blood count ≥ 3.6x10E3/mm3 or ≥ 3.6x10E9/L, absolute granulocyte count ≥1.5x10E3/mm3 or ≥1.5x10E9/L, absolute lymphocyte count ≥0.5x10E3/mm3 or ≥0.5x10E9/L, and platelet count ≥100x10E3/mm3 or ≥100x10E9/L).
https://www.clinicaltrialsregister.eu/ctr-search/trial/2011-001977-13/DE
Absolute lymphocyte count (ALC) was?>?800 cells/mm3 in 48.6% of the patients (n?=?161) and was?<?800 cells/mm3 in 51.4% of patients (n?=?170), a characteristic that has been associated with poor prognosis after radiation.
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-018-1507-6
Abstract
Background: The immune system plays an important role in cancer surveillance and therapy. Chemoradiation can cause severe treatment-related lymphopenia (TRL) (<500 cells/mm3) that is associated with reduced survival. Materials and Methods: Data from 4 independent solid tumor studies on serial lymphocyte counts, prognostic factors, treatment, and survival were collected and analyzed. The data set included 297 patients with newly diagnosed malignant glioma (N=96), resected pancreatic cancer (N=53), unresectable pancreatic cancer (N=101), and non–small cell lung cancer (N=47). Results: Pretreatment lymphocyte counts were normal in 83% of the patient population, and no patient had severe baseline lymphopenia. Two months after initiating chemoradiation, 43% developed severe and persistent lymphopenia (P=.001). An increased risk for death was attributable to TRL in each cancer cohort (gliomas: hazard rate [HR], 1.8; 95% CI, 1.13–2.87; resected pancreas: HR, 2.2; 95% CI, 1.17–4.12; unresected pancreas: HR, 2.9; 95% CI, 1.53–5.42; and lung: HR, 1.7; 95% CI, 0.8–3.61) and in the entire study population regardless of pathologic findings (HR, 2.1; 95% CI, 1.54–2.78; P<.0001). Severe TRL was observed in more than 40% of patients 2 months after initiating chemoradiation, regardless of histology or chemotherapy regimen, and was independently associated with shorter survival from tumor progression. Conclusions: Increased attention and research should be focused on the cause, prevention, and reversal of this unintended consequence of cancer treatment that seems to be related to survival in patients with solid tumors.
https://jnccn.org/view/journals/jnccn/13/10/article-p1225.xml
sharpie510,
I agree. Linda Liau (2017):
“More than 95% of the time, these tumors come back in a year or two, so the goal is to prevent this tumor from coming back,” Liau said. “It all boils down to inducing the body’s immune system to recognize the tumor as foreign somehow.”
sukus,
The Company currently relies upon contract manufacturers for production of its DCVax products, research and development services, distribution and logistics, and related services, in compliance with the Company’s specifications and the applicable regulatory requirements. The companies are Cognate BioServices in the U.S. and Advent BioServices (a related party) in the U.K. Both of these companies specialize in the production of living cell products.
Autolomous
5h ago
Super excited to be executing Operational Qualification of the Autolomous eBMR for Advent Bioservices at their current manufacturing location. Looking forward to deploying further modules and the transition to their new 75,000ft Cell & Gene Manufacturing Facility under commissioning.
Happy and Excited to announce that we have been working with Advent Bioservices on developing & deploying our AutoloMATE eBMR solution. We look forward to continuing our partnership with Mike Scott and the Advent Team.